Glioblastoma is ‘hot’ for personalized vaccines

Baratta, Maria Giuseppina

doi:10.1038/s41568-019-0118-8

Cited by 16 publications

(13 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the central nervous system (CNS) has been considered an immune‐privileged site, this dogma has now shifted towards a paradigm where there is room for two crucial aspects in immunotherapy: CNS infiltration of antigen‐specific T cells, and a draining lymphatic system [16]. Thanks to this paradigm shift, potentiating T cells to infiltrate and kill glioblastomas has become an appealing immunotherapeutic option [17–26]. Different types of immunotherapy, including peptide‐based vaccines [27], autologous vaccines, checkpoint inhibition and adoptive dendritic cells (DCs) and T cells have emerged with some showing encouraging results [19–25].…”

Section: Introductionmentioning

confidence: 99%

Glycan modification of glioblastoma‐derived extracellular vesicles enhances receptor‐mediated targeting of dendritic cells

Dusoswa

Horrevorts

Ambrosini

et al. 2019

J of Extracellular Vesicle

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Glycan modification of glioblastoma‐derived extracellular vesicles enhances receptor‐mediated targeting of dendritic cells

Dusoswa

Horrevorts

Ambrosini

et al. 2019

J of Extracellular Vesicle

View full text Add to dashboard Cite

show abstract

“…The title of a very recent Nature article states, “Glioblastoma is ‘hot’ for personalized vaccines” (Baratta, ). Nanotechnology could play a role in this ‘hot’ field by engaging immune cells.…”

Section: Nanoparticle‐based Immunotherapy Of Gliomamentioning

confidence: 99%

Immunoengineering in glioblastoma imaging and therapy

Zanganeh

Georgala

Corbo

et al. 2019

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Patients diagnosed with glioblastoma have poor prognosis. Conventional treatment strategies such as surgery, chemotherapy, and radiation therapy demonstrated limited clinical success and have considerable side effects on healthy tissues. A central challenge in treating brain tumors is the poor permeability of the blood–brain barrier (BBB) to therapeutics. Recently, various methods based on immunotherapy and nanotechnology have demonstrated potential in addressing these obstacles by enabling precise targeting of brain tumors to minimize adverse effects, while increasing targeted drug delivery across the BBB. In addition to treating the tumors, these approaches may be used in conjunction with imaging modalities, such as magnetic resonance imaging and positron emission tomography to enhance the prognosis procedures. This review aims to provide mechanistic understanding of immune system regulation in the central nervous system and the benefits of nanoparticles in the prognosis of brain tumors. This article is characterized under: Diagnostic Tools > in vivo Nanodiagnostics and Imaging Nanotechnology Approaches to Biology > Cells at the Nanoscale Nanotechnology Approaches to Biology > Nanoscale Systems in Biology

show abstract

“…The cargo-based delivery of therapeutic agents, which induce an immune response, is a topic of high interest in glioma treatment, as highlighted in a recent article, “glioblastoma is ‘hot’ for personalized vaccines” [ 90 ]. A detailed schematic illustration of the immune response in glioblastoma is shown in Fig.…”

Section: Nanomedicine-based Immunotherapy For Glioblastomamentioning

confidence: 99%

Nanomedicine-based immunotherapy for central nervous system disorders

et al. 2020

View full text Add to dashboard Cite

Central nervous system (CNS) disorders represent a broad spectrum of brain ailments with short- and long-term disabilities, and nanomedicine-based approaches provide a new therapeutic approach to treating CNS disorders. A variety of potential drugs have been discovered to treat several neuronal disorders; however, their therapeutic success can be limited by the presence of the blood-brain barrier (BBB). Furthermore, unique immune functions within the CNS provide novel target mechanisms for the amelioration of CNS diseases. Recently, various therapeutic approaches have been applied to fight brain-related disorders, with moderate outcomes. Among the various therapeutic strategies, nanomedicine-based immunotherapeutic systems represent a new era that can deliver useful cargo with promising pharmacokinetics. These approaches exploit the molecular and cellular targeting of CNS disorders for enhanced safety, efficacy, and specificity. In this review, we focus on the efficacy of nanomedicines that utilize immunotherapy to combat CNS disorders. Furthermore, we detailed summarize nanomedicine-based pathways for CNS ailments that aim to deliver drugs across the BBB by mimicking innate immune actions. Overview of how nanomedicines can utilize multiple immunotherapy pathways to combat CNS disorders.

show abstract

Glioblastoma is ‘hot’ for personalized vaccines

Abstract: OrIgInAl ArTIclE Ruscetti, M. et al. NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination.

Cited by 16 publications

References 2 publications

Glycan modification of glioblastoma‐derived extracellular vesicles enhances receptor‐mediated targeting of dendritic cells

Glycan modification of glioblastoma‐derived extracellular vesicles enhances receptor‐mediated targeting of dendritic cells

Immunoengineering in glioblastoma imaging and therapy

Nanomedicine-based immunotherapy for central nervous system disorders

Contact Info

Product

Resources

About